Mesa Laboratories, Inc. reported $250M of revenue over the trailing twelve months, +3.0% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $250M (to Q1 2027). Net income: $4.8M, trailing twelve months to Q1 2027. Free cash flow: $53M, trailing twelve months to Q1 2027. Operating margin: 9.0%, trailing twelve months to Q1 2027.

MLABMesa Laboratories, Inc.

Technology

$125.99+86% 1Y

$125.99

$67.3852 weeks$142.52

MLAB as reported

Mesa Laboratories, Inc. reported $250M of revenue over the trailing twelve months, +3.0% on the year before. 11 reported series are charted on this page, each one as filed.

$250M

Revenue, trailing twelve months · to Q1 2027 · +3.0% against the twelve months before

Net income: $4.8M
Net income · −874% year on year · trailing twelve months to Q1 2027
Free cash flow: $53M
Free cash flow · +57% year on year · trailing twelve months to Q1 2027
Operating margin: 9.0%
Operating margin · trailing twelve months to Q1 2027

Details›

Every series Ryufin has for MLAB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$250M	+3.0%	Q1 2027
Net income	$4.8M	−874%	Q1 2027
EPS	$0.85	−754%	Q1 2027
Gross margin	64%	n/a	Q1 2027
Operating margin	9.0%	n/a	Q1 2027
Net margin	2.0%	n/a	Q1 2027
ROE	1.8%	n/a	Q1 2027
ROA	0.80%	n/a	Q1 2027
ROIC	6.3%	n/a	Q1 2027
Free cash flow	$53M	+57%	Q1 2027
P/E	148	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.